Nordic Pharma Announces Launch of Lacrifill® Canalicular Gel in the United Kingdom (UK)
Theale, United Kingdom – 23rd February 2026 – Nordic Pharma UK Limited, a subsidiary of Nordic group B.V, an international pharmaceutical company operating as Nordic Pharma, announced today the introduction of Lacrifill®, a novel therapy for dry eye, in the UK. Following USA launch in 2024 and CE mark approval in 2025, Lacrifill® is now available to healthcare professionals and patients in the UK, marking a major step in the treatment of dry eye disease.
Lacrifill® is a cross-linked hyaluronic acid gel designed to temporarily block tear drainage by physiologically occluding the canalicular system. By enhancing tear film preservation, Lacrifill® helps maintain natural lubricating tears on the patients’ ocular surface, offering an individualised approach to dry eye management. The in-clinic procedure provides a full fill of the canalicular system and delivers long-lasting effects for up to six months.
Dry eye disease (DED) is a highly prevalent condition and represents a particular challenge in patients undergoing ocular surgical procedures such as cataract and LASIK surgery. Up to 75% of patients scheduled for cataract surgery are reported to suffer from DED1, which can lead to fluctuating vision, dissatisfaction and increased symptoms after surgery.2 In refractive surgery, approximately 95% of patients experience some form of dry eye directly after the procedure,3 making it the most common cause of patients being ‘20/20 unhappy’ following LASIK.4
“Introducing Lacrifill® to the UK market marks an important achievement for Nordic Pharma,” stated Charlotte Watchorn, General Manager of Nordic Pharma UK. “We’re delighted to offer this advanced dry eye treatment to UK clinicians and patients. We anticipate that Lacrifill® will benefit numerous individuals affected by dry eye disease and will serve as a valuable option in dry eye care, especially in relation to ocular surgical procedures.”
To set up an account to order Lacrifill® email: [email protected]
Register your interest: https://www.lacrifill.info/
View Lacrifill® Instructions For Use & adverse event reporting: https://www.nordicpharma.co.uk/pils-and-smpcs/
About Nordic Group B.V.
Nordic Group B.V. is a privately owned, medium-sized international pharmaceutical company focused on the development and commercialisation of specialty products. Its portfolio includes innovative therapies in Ophthalmology, Rheumatology, and Women’s Health. With strong roots across Europe, Nordic Group B.V. now has affiliates in Canada, the US and Japan and continues to expand globally through strategic acquisitions and partnerships.
For more information about Nordic Pharma, visit http://www.nordicpharma.co.uk
References:
| 1. | Trattler WB, et al. Clin Ophthalmol. 2017 Aug;11:1423–1430. |
| 2. | Starr CE, et al. J Cataract Refract Surg. 2019 May;45(5):669–684. |
| 3. | Yu EYW, et al. Ophthalmology. 2000 Dec;107(12):2131–5. |
| 4. | De Gregorio C, et al. J Clin Med. 2025 Feb;14(5):1408. |
